Role of Retina in Mechanisms of Illusions and Visual Hallucinations Observed in Idiopathic Parkinson's Disease
NCT ID: NCT03454269
Last Updated: 2019-03-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
90 participants
INTERVENTIONAL
2018-03-08
2020-03-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Investigator hypothesize that illusions could be related to a visual impairment, maybe at the retinal level, known to be impaired in PD, whereas Visual hallucinations would be due to a more widespread impairment affecting higher levels visuo-perceptive and cognitive functions.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Hallucinations in Parkinson's Disease
NCT04592965
Phenomenological and Psychopathological Factors Associated to Hallucinations in Parkinson's Disease
NCT03105401
Presence Hallucination in Parkinson's Disease
NCT04579887
Assessment of Three-dimensional Vision Alteration in Parkinson Disease
NCT01620164
Visual Selective Attention in Parkinson's Disease
NCT01135407
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Thus illusions and minorVH may have a different pathogenesis and a different prognosis compared to complex VH, however studies exploring the structural and functional changes associated with hallucinations in PD have mainly included patients with well-structured VH and moderate to severe cognitive impairment , making it difficult to define early abnormalities associated with minor hallucinations or illusions.
Several hypotheses are proposed regarding the emergence of hallucinations in PD.
* It has been first suggested that hallucinations in PD could be mainly the result of a chronic exposition to dopaminergic therapy . However, the description of hallucination in untreated PD patients goes against that solely explication . Besides, no strong link has been identified between the occurrence of VH and the dosage and duration of dopaminergic treatment . This suggests that Dopaminergic treatment would not directly cause VH but could be a precipiting factor.
* Sleep-wake cycle disturbances have also been reported as risk factors for the occurrence of VH in PD , and particularly the presence of REM Sleep behavior disorders (RBD) . The emergence of VH in PD patients coinciding with daytime episodes of REM sleep may be dream imagery occurring during wake , however this hypothesis is still debated.
* Other risk factors have been associated with VH in PD such as the disease duration, motor symptom severity and mostly cognitive impairment. Indeed, VH occur mainly in PD patients with cognitive decline , but also VH are predictive of dementia . In fact, cognitive impairment in PD patients, and particularly visuoperceptive impairment, would lead to an impaired processing of visual information. Indeed, impaired frontal and parietal cortical activation have been reported in PD patients with VH while being presented visual stimulations, suggesting a diminished answer to external perceptions in posterior cortical areas associated with an increased frontal abnormal activity leading to the emergence of sensorial visual experiences . This shifting visual circuitry from posterior to anterior regions associated with attention process impairment may play a role in the pathophysiology of VH in PD. Thus, the occurrence of Visual Hallucinations in PD Patients appears to be due to a desinhibition of the "top-down" visual stream leading to the emergence of internal mental imagery stocked in memory, and interpreted like visual perceptions coming from the external environment .
* Yet, some evidences also points out to an impaired "bottom-up" processing that could lead to the emergence of VH in PD. Indeed, a dopaminergic denervation and alpha synuclein aggregation have been demonstrated in the retina of PD Patients , even at early stages of the disease . However the functional consequences of such a denervation are still poorly understood , even if impaired contrast discrimination and color vision impairment are widely described in PD . One study has reported an association between retinal impairment, measured with OCT, and VH in PD .
Thus, the emergence of VH and illusions in PD could be due to an inbalance between a hypoactivated "bottom-up" (due to retino-striato-occipital hypoactivation) and a deshinibited "top-down" (mainly frontal) visual stream. However in all these studies, Hallucinations and illusions were not specifically discriminated and investigated in spite of the fact that they could be subtended by different pathophysiological mechanisms and might imply different prognosis for the evolution of the disease.
Investigator hypothesize that illusions, which represent the failure to successfully integrate stimuli that have been physically presented, could be more related to "bottom up" impairment, unlike Hallucinations, which occur where there is perception in the absence of any stimulus and could be more related to a "top down" impairment. Thus, PD patients with illusions (PD-I) might present greater retinal degeneration measured by OCT compared to PD patients with Visual hallucinations (PD-VH) and PD patients without Hallucinations or illusion (PD-nVHI), suggesting a sensorial deprivation underlying these disturbed visual perceptions of reality. Visual Hallucinations that are more elaborated would require a more widespread cognitive disorder, with increased cognitive and visuoperceptive dysfunction.
OBJECTIVE In this study investigator aim to compare PD patients with visual hallucinations (PD-VH), with illusions (PD-I), without Visual hallucinations or illusions (PD-nVHI) regarding retinal degeneration in OCT and cognitive functions (visuoperceptive and attentional functions) in order to determine whether PD-I might show greater retinal degeneration compared to PD-VH, and lesser cognitive impairment.
DESIGN OF STUDY:
Investigator will include 30 PD-VH+, 30 PD-I+, 30 PD-VH-I- among the patients consulting at our center.
During the first visit (Baseline, inclusion visit, 2 hours), each subject will perform a clinical and neurological examination with : • Diagnosis of PD according to UKPDBB criteria.
• The presence of Visual Hallucinations or Illusions will be characterized according to the Psychosensory Hallucination Scale. Illusions will be defined by answering "Yes" to at least one of the "elementary items".
During the second visit (Day 15, one day), each patient will have a neurological, neuropsychological and ophthalmological examination with an evaluation of
* the severity of the disease (Hoehn and Yahr score, Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS))
* the cognitive impairment (Montreal Cognitive Assessment, Evaluation of visuo-perceptive functions and attention)
* the excessive diurnal Somnolence and sleep attacks
* the visual acuity, intraocular pressure, Optical Coherence Tomography (OCT), contrast and colour evaluations.
Circumstances of emergence and distress caused by Hallucinations/illusions was also evaluated by measurement of heart rate variability, electrodermal recording, spy glasses and self-evaluation of Stress.
Finally, each subject will have a Magnetic Resonance Imaging (MRI) acquisition.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
PD patients with visual hallucinations (PD-VH)
PD patients without hallucinations or illusions
Optical Coherence Tomography
The Optical Coherence Tomography is a painless analysis without contact with the eye. Patients are sitting in front of the machine. Each eye is analyzed. By a laser scanning system, longitudinal sections of the retina are made at the level of the macula and the optic nerve. The device automatically segments the different layers which are then measurable (in microns) by the ophthalmologist (duration of the analysis: 3 minutes).
Patients with illusions (PD-I)
PD patients with Illusions and without hallucinations
Optical Coherence Tomography
The Optical Coherence Tomography is a painless analysis without contact with the eye. Patients are sitting in front of the machine. Each eye is analyzed. By a laser scanning system, longitudinal sections of the retina are made at the level of the macula and the optic nerve. The device automatically segments the different layers which are then measurable (in microns) by the ophthalmologist (duration of the analysis: 3 minutes).
Patients without visual hallucinations or illusions (PD-nVHI))
PD patients without Illusions and with hallucinations
Optical Coherence Tomography
The Optical Coherence Tomography is a painless analysis without contact with the eye. Patients are sitting in front of the machine. Each eye is analyzed. By a laser scanning system, longitudinal sections of the retina are made at the level of the macula and the optic nerve. The device automatically segments the different layers which are then measurable (in microns) by the ophthalmologist (duration of the analysis: 3 minutes).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Optical Coherence Tomography
The Optical Coherence Tomography is a painless analysis without contact with the eye. Patients are sitting in front of the machine. Each eye is analyzed. By a laser scanning system, longitudinal sections of the retina are made at the level of the macula and the optic nerve. The device automatically segments the different layers which are then measurable (in microns) by the ophthalmologist (duration of the analysis: 3 minutes).
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients affiliated to a health insurance company.
* HV-/IV+ Group : patients presenting illusions criteria according to SCOPA, with no visual hallucinations
* HV+/IV- Group : patients presenting visual hallucinations (SCOPA) without illusions
* HV-/IV- Group : patients without hallucinations or illusions SCOPA)
Exclusion Criteria
* Patients with active psychiatric pathologies (psychosis).
* Patients unable to remain sit and still during different ophtalmological exams due to camptocormia and dyskinesias.
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fondation de France
OTHER
University Hospital, Clermont-Ferrand
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ana MARQUES
Role: PRINCIPAL_INVESTIGATOR
University Hospital, Clermont-Ferrand
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU Clermont-Ferrand
Clermont-Ferrand, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Marques A, Beze S, Lambert C, Bonamy L, de Chazeron I, Rieu I, Chiambaretta F, Durif F. Psycho-sensory modalities of visual hallucinations and illusions in Parkinson's disease. Rev Neurol (Paris). 2021 Dec;177(10):1228-1236. doi: 10.1016/j.neurol.2021.04.007. Epub 2021 Jul 5.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2017-A02605-18
Identifier Type: OTHER
Identifier Source: secondary_id
CHU-380
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.